(1) Background: Epilepsy is a frequent comorbidity in patients with brain tumors, in whom
seizures are often drug-resistant. Current evidence suggests that excess of glutamatergic …

Brain tumor-related epilepsy (BTRE) is a common comorbidity in patients with brain
neoplasms and it may be either the first symptom or develop after the tumor diagnosis …

Abstract Introduction: Epilepsy occurs in 35–70% of patients with gliomas; glutamate plays a
central role via AMPA-receptor activation, which is involved both in seizure activity and …

Background: Epilepsy is one of the most common symptoms of brain tumors. It is often drug
resistant and generally worsen patients' quality of life (QoL). Brain tumors release glutamate …

Objective Possible loss of efficacy and potential interactions between antiepileptic drugs
(AEDs) and chemotherapy could complicate the management of patients with brain tumor …

We report a retrospective monocentric study performed on 63 patients affected by epilepsy
with known etiology, receiving perampanel as add-on therapy with at least 12-month follow …

Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either …

Epilepsy is one of the most common chronic neurological disorder affecting around 70
million people worldwide. Although long-term seizure control can be achieved in most cases …

Objectives Evaluate interim long‐term tolerability, safety and efficacy of adjunctive
perampanel, a novel α‐amino‐3‐hydroxy‐5‐methyl‐5‐isoxazolepropionic acid (AMPA) …

Introduction: Perampanel is an antiepileptic drug approved in the USA and Europe as
monotherapy and adjunctive therapy for focal onset seizures and as adjunctive therapy for …